Aradigm Corporation (ARDM) Releases Quarterly Earnings Results, Beats Estimates By $0.37 EPS

Aradigm Corporation (NASDAQ:ARDM) announced its quarterly earnings data on Thursday. The company reported $0.07 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.37, Bloomberg Earnings reports. The firm had revenue of $7.68 million during the quarter. Aradigm Corporation had a negative net margin of 196.65% and a negative return on equity of 3,432.80%.

Aradigm Corporation (NASDAQ ARDM) opened at 1.37 on Friday. The stock’s market capitalization is $20.28 million. Aradigm Corporation has a 12 month low of $0.78 and a 12 month high of $7.19. The company has a 50 day moving average of $1.34 and a 200 day moving average of $1.52.

Separately, Zacks Investment Research raised shares of Aradigm Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, July 11th.

ILLEGAL ACTIVITY NOTICE: “Aradigm Corporation (ARDM) Releases Quarterly Earnings Results, Beats Estimates By $0.37 EPS” was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.com-unik.info/2017/08/12/aradigm-corporation-ardm-releases-quarterly-earnings-results-beats-estimates-by-0-37-eps.html.

About Aradigm Corporation

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies.

Earnings History for Aradigm Corporation (NASDAQ:ARDM)

What are top analysts saying about Aradigm Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aradigm Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit